Johnson & Johnson Vision Presents Data Validating Improved Surgical Outcomes and Surgeon Satisfaction Across Cataract and Refractive Portfolio and the Latest in IOL Evaluation Techniques at the 2022 ASCRS Annual Meeting

JJ Vision

Latest Study Shows TECNIS Synergy IOL Provides Wide Range of Functional Binocular Vision

New Data Reinforces Excellent Rotational Stability with TECNIS Eyhance Toric II IOL

Studies Shows High Surgeon Satisfaction and Positive Outcomes with VERITAS Vision System and its New Swivel Handpiece, and Patient Preference for LASIK over SMILE

Latest Evidence Provides New Insights About the Utility of MTF when Evaluating IOL Contrast Differences Over a Range of Defocus 

IRVINE, Calif. – April 20, 2022 – Johnson & Johnson Vision*, a global leader in eye health and part of Johnson & Johnson MedTech**, will present and/or support 46 company-sponsored and investigator-led*** studies evaluating innovations and outcomes across its surgical portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 22-26. A complete listing of abstracts and events can be found on the ASCRS website

"We take an outcomes-led approach to innovation, incorporating input from surgeons to develop evidenced-based solutions that help them improve their patients' sight and quality of life,” said Rajesh Rajpal,**** MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision. "At ASCRS this year, we’re thrilled to present a robust slate of data reinforcing the technological advances and improved outcomes offered by our TECNIS family of IOLs and our innovative surgical systems.” 

At the meeting, Johnson & Johnson Vision will also introduce the next-gen TearScience Activator Clear, a new Activator for the TearScience LipiFlow Thermal Pulsation System that provides greater treatment precision, created with the environment in mind. Surgeons can view this new technology at the       Johnson & Johnson Vision booth (#1837), which will also feature some of the latest innovations in cataract care, including the TECNIS Synergy IOL, TECNIS Eyhance IOL and VERITAS Vision System. Additional information can be found at jnjvisionpro.com/join-us-ascrs-2022
 

Highlights of Data to be Presented at the Meeting

Evidence Shows Wide Range of Functional Binocular Vision with TECNIS Synergy IOL***

Many people who have cataracts also experience presbyopia. Cataract surgery provides a unique opportunity to address the condition without an additional procedure. Data on the TECNIS Synergy IOL, a breakthrough lens designed to deliver a wider* range of continuous vision**,1 will show that it provided a wide range of functional binocular vision, from distance to intermediate, to near (33cm).

  1. Paper Presentation: “Visual Outcomes of New Continuous Range of Vision Presbyopia-Correcting Intraocular Lens Under Photopic Light Conditions.” De Rojas J. (Abstract #80844). Monday, April 25, 2022, 10:05 AM - 10:10 AM, WEWCC - Level 1, 143C.
     

Evidence Shows TECNIS Eyhance IOLs Improve Visual Acuity and Provide Excellent Rotational Stability 

The TECNIS Eyhance IOLs are a next-generation monofocal lens created to provide high-quality vision from day to night, including for patients with astigmatism, delivering not only high-quality distance vision, but also better low-light image contrast.2,3 Data to be presented shows that the TECNIS IOLs improve visual acuity, with the Toric II lens providing excellent rotational stability. And with contrast sensitivity being an important element of vision that impacts health related quality of life and safety,4 an additional study supports considering image contrast differences when selecting an IOL. 

  1. Paper Presentation: “Visual Acuity Outcomes Post-Implantation of a New Monofocal IOL Using Different Target Refractions.” Sandoval H. (Abstract #82285). Saturday, April 23, 2022, 3:40 PM - 3:45 PM, WEWCC - Level 1, 144A.
  2. Paper Presentation: “Tolerance to Induced Astigmatism: Comparison of Standard and Enhanced Monofocal IOLs.” Rocha K. (Abstract #82792). Sunday, April 24, 2022, 1:35 PM - 1:40 PM, WEWCC - Level 1, 144A.
  3. Paper Presentation: “Subjective and Objective Assessments of Performance of a Toric Intraocular Lens with Modified Haptics.” Quesada G. (Abstract #83298. Monday, April 25, 2022, 10:46 AM - 10:51 AM, WEWCC - Level 1, 144A.
  4. Paper Presentation: “Objective Metrics for Quantifying Monofocal and Presbyopia-Correcting IOL Contrast Performance.” Chang D. (Abstract #84997). ASCRS Electronic Posters (On-Demand).
     

Studies Show Good Visual Acuity Outcomes and High Rates of Surgeon Satisfaction with VERITAS Vision System and Patient Preference for LASIK over SMILE 

When choosing an ocular surgical technology, understanding surgeon and patient experience may provide helpful context for decision-making. Data to be presented shows that surgeons achieve good visual acuity outcomes for their patients and report high satisfaction with the overall performance of the VERITAS Vision System and its new swivel handpiece, a next-generation phacoemulsification (phaco) system designed to address patient safety, surgeon efficiency and comfort. In a second study evaluating patient-reported quality of vision in LASIK and SMILE procedures, more patients preferred the vision provided by LASIK, with similar rates reported of adverse visual symptoms.

  1. Paper Presentation: “Evaluation of Surgeon Satisfaction and Visual Outcomes of a Dual Mode Phacoemulsification System.” Quesada G. (Abstract #82436). Monday, April 25, 2022, 8:28 AM - 8:33 AM, WEWCC - Level 1, 143B.
  2. Paper Presentation: “Patient-Reported Quality of Vision in a Prospective Randomized Trial Comparing LASIK and SMILE.” Ma K. (Abstract #83533). Monday, April 25, 2022, 10:28 AM - 10:33 AM, WEWCC - Level 1, 143B.

All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.


About The TECNIS Family of IOLs 
At Johnson & Johnson Vision, quality begins with the platform. The TECNIS platform uses a proprietary combination of materials and design to deliver more for patients – more clarity with lower reflectance/lower dispersion vs competitor platform,5,6,7‡ low levels of chromatic aberration8‡‡, and almost complete elimination of spherical aberration.9 The TECNIS portfolio also delivers more image contrast - day and night - than the leading competitor platform,10,11‡‡‡ and more stability to stand the test of time.8,12,13‡‡‡‡ Finally, TECNIS delivers more choice for surgeons and patients — offering the broadest portfolio of IOLs, with solutions for vision across a variety of different visual conditions and lifestyles.14

About Johnson & Johnson Vision
At Johnson & Johnson Vision, part of Johnson & Johnson MedTech, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook

About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.
 

INDICATIONS AND IMPORTANT SAFETY INFORMATION for the TECNIS® Family of 1-Piece IOLs 

Rx Only

INDICATIONS and IMPORTANT SAFETY INFORMATION for TECNIS SYMFONY™ and TECNIS SYMFONY™ TORIC EXTENDED RANGE OF VISION IOLs
The TECNIS Symfony™ Extended Range of Vision IOL, Model ZXR00, is indicated for primary implantation for the visual correction of aphakia, in adult patients with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed.  The TECNIS Symfony™ Toric Extended Range of Vision IOLs, Models ZXT150, ZXT225, ZXT300, and ZXT375, are indicated for primary implantation for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. These models of IOLs, ZXR00, ZXT150, ZXT225, ZXT300, and ZXT375, mitigate the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, these models of IOLs provide improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. These models of IOLs are intended for capsular bag placement only.

INDICATIONS and IMPORTANT SAFETY INFORMATION for TECNIS SYMFONY™ OPTIBLUE™ and TECNIS SYMFONY™ TORIC II OPTIBLUE™ EXTENDED RANGE OF VISION IOLs
The TECNIS Symfony™ OptiBlue™ Extended Range of Vision IOL, Model ZXR00V, is indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS Symfony™ Toric II OptiBlue™ Extended Range of Vision IOLs, Models ZXW150, ZXW225, ZXW300, ZXW375, are indicated for primary implantation for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. These models of IOLs, ZXR00V, ZXW150, ZXW225, ZXW300, ZXW375, mitigate the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, these models of IOLs provide improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. These models of IOLs are intended for capsular bag placement only.

INDICATIONS and IMPORTANT SAFETY INFORMATION for TECNIS SYNERGY™ and TECNIS SYNERGY™ TORIC II IOLs
The TECNIS Synergy™ IOL, Model ZFR00V, is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Synergy™ IOL mitigates the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only. The TECNIS Synergy™ Toric II IOL, Models ZFW150, ZFW225, ZFW300, ZFW375, are indicated for primary implantation for the visual correction of aphakia and for the reduction of refractive astigmatism in adult patients, with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Synergy™ Toric II IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only.

Indications for the TECNIS® 1-Piece Monofocal IOL 
TECNIS® 1-piece lenses are indicated for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. These devices are intended to be placed in the capsular bag.

INDICATIONS FOR THE TECNIS® MULTIFOCAL 1-PIECE AND TECNIS® MULTIFOCAL TORIC II IOLs
The TECNIS® Multifocal 1-Piece intraocular lenses are indicated for primary implantation for the visual correction of aphakia in adult patients with and without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire near, intermediate, and distance vision with increased spectacle independence. The TECNIS® Multifocal Toric II lens models ZKU150, ZKU225, ZKU300, ZKU375 and ZLU150, ZLU225, ZLU300, ZLU375 are indicated for primary implantation for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients with or without presbyopia, with greater than or equal to 1 diopter of preexisting corneal astigmatism, in whom a cataractous lens has been removed in order to provide near, intermediate and distance vision. The IOLs are intended for capsular bag placement only.

INDICATIONS FOR THE TECNIS® TORIC II 1-PIECE AND TECNIS® TORIC 1-PIECE IOLs 
The TECNIS® Toric II 1-Piece and TECNIS® Toric 1-Piece IOL posterior chamber lens is indicated for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire improved uncorrected distance vision, reduction in residual refractive cylinder, and increased spectacle independence for distance vision. The device is intended to be placed in the capsular bag.

INDICATIONS FOR THE TECNIS EYHANCE™ AND TECNIS EYHANCE™ TORIC II IOLs
The TECNIS Eyhance™ IOL, Model ICB00 is indicated for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. The TECNIS Eyhance™ Toric II IOLs, Models ICU150-ICU600, are indicated for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag.

WARNINGS: Physicians considering lens implantation under any of the conditions described in the Directions for Use should weigh the potential risk/benefit ratio prior to implanting a lens that could increase complications or impact patient outcomes. Do not place the lens in the ciliary sulcus. Inform patients about the possibility that a decrease in contrast sensitivity and an increase in visual disturbances may affect their ability to drive a car under certain environmental conditions, such as driving at night or in poor visibility conditions.

Rotation of the TECNIS® Toric, TECNIS® Toric II 1-Piece, TECNIS Eyhance™ Toric II and TECNIS Symfony™ Toric II OptiBlue™ IOLs away from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. All preoperative surgical parameters are important when choosing a toric lens for implantation. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case.

PRECAUTIONS: Prior to surgery, inform prospective patients of the possible risks and benefits associated with the use of this device and provide a copy of the patient information brochure to patient. The long-term effects of intraocular lens implantation have not been determined. Secondary glaucoma has been reported occasionally in patients with controlled glaucoma who received lens implants. Do not reuse, resterilize or autoclave. The safety and effectiveness of the TECNIS Eyhance™ IOLs have not been substantiated in clinical trials and the effects of the optical design on quality of vision, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have not been evaluated clinically.

ADVERSE EVENTS:  The most commonly reported adverse events that occurred during the clinical trials of the TECNIS® 1-Piece lenses were macular edema and secondary surgical re-intervention.

ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

INDICATIONS AND IMPORTANT SAFETY INFORMATION for the VERITAS™ Vision System

Rx Only

INDICATIONS FOR USE: The VERITAS™ Vision System is a modular ophthalmic microsurgical system that facilitates anterior segment (i.e., cataract) ophthalmic surgery. The modular design allows the users to configure the system to meet their surgical requirements

IMPORTANT SAFETY INFORMATION: Risks and complications of cataract surgery may include corneal burn. This device is only to be used by a trained licensed physician

ATTENTION: Reference the labeling for a complete listing of Indications and Important Safety Information

INDICATIONS AND IMPORTANT SAFETY INFORMATION for the STAR S4 IR® Excimer Laser System and the iDESIGN® Refractive Studio for Wavefront-Guided Photorefractive Keratectomy (PRK)

INDICATIONS: The STAR S4 IR® Excimer Laser System and the iDESIGN® Refractive Studio is indicated for wavefront-guided photorefractive keratectomy (PRK) in patients: with myopia, with or without astigmatism, as measured by iDESIGN® Refractive Studio System with spherical equivalent up to -8.00 D, and cylinder up to -3.00 D, with agreement between manifest refraction (adjusted for optical infinity) and iDESIGN® Refractive Studio System refraction as follows: Spherical Equivalent: Magnitude of the difference is less than 0.625 D, Cylinder: Magnitude of the difference is less than or equal to 0.5 D, in patients 18 years of age or older; with refractive stability (a change of ≤1.0 D in manifest refraction spherical equivalent for a minimum of 12 months prior to surgery), and with wavefront capture diameter of at least 4 mm. 

CONTRAINDICATIONS: iDESIGN® System driven PRK surgery  is contraindicated in patients with any type of active connective tissue disease or autoimmune disease, in patients with signs of keratoconus, abnormal corneal topography, and degenerations of the structure of the cornea, in patients whose corneal thickness would cause anticipated treatment would violate the posterior 250 microns (μm) of corneal stroma, in patients with uncontrolled diabetes, in patients with active eye infection or active inflammation, in patients with recent herpes eye infection or problems resulting from past infection, in patients with significant dry eyes. If the patients have severely dry eyes, PRK may increase the dryness. This may or may not go away. Severe eye dryness may delay healing or interfere with the surface of the eye after surgery. It may result in poor vision after PRK.

WARNINGS AND PRECAUTIONS: iDESIGN® System driven PRK surgery is not recommended in patients have systemic diseases that may affect wound healing, such as controlled autoimmune, or connective tissue disease, or controlled diabetes, have an immunocompromised status or take medications that may result in a weakened immune system such as antimetabolites for any medical conditions or affect wound healing such as Isotretinoin (Accutane), have a history of Herpes simplex or Herpes zoster keratitis, have glaucoma, In patients with a cardiac pacemaker, implanted defibrillator or other implanted electronic device, have mild to moderate dry eye, have decreased vision in one eye (e.g., amblyopia). Surgeons are reminded that they should instruct the patient to fixate on the Patient Fixation LED during surgery with or without the use of the ActiveTrak System. Please refer to Operator’s Manual for a list of additional Precautions.

CAUTION: U.S. Federal law restricts this device to sale, distribution, and use by or on the order of a physician or other licensed eye care practitioner who has been trained in the calibration and operation of this device.

ADVERSE EVENTS: Please refer to Operator’s Manual for a list of Adverse Events and Complications in clinical studies for wavefront-guided PRK Patients with Myopia and Myopic Astigmatism. 

warnings

INDICATIONS AND IMPORTANT SAFETY INFORMATION for TearScience® LipiFlow® Thermal Pulsation System

Rx Only

INDICATIONS: The TearScience® LipiFlow® Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye.

CONTRAINDICATIONS: Do not use the TearScience® LipiFlow® System in patients with the following conditions.  Use of the device in patients with these conditions may cause injury. Safety and effectiveness of the device have not been studied in patients with these conditions.

  • Ocular surgery within prior 3 months, including intraocular, oculo-plastic, corneal or refractive surgery procedure
  • Ocular injury within prior 3 months
  • Ocular herpes of eye or eyelid within prior 3 months
  • Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids including a hordeolum or stye)
  • Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months (e.g., retinitis, macular inflammation, choroiditis, uveitis, iritis, scleritis, episcleritis, keratitis)
  • Eyelid abnormalities that affect lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis)
  • Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy)

PRECAUTIONS: Use of the TearScience® LipiFlow® System in patients with the conditions described in the TearScience® LipiFlow® instructions for use may result in reduced treatment effectiveness because these conditions may cause ocular symptoms unrelated to cystic meibomian glands and require other medical management.  Safety and effectiveness of the device have not been studied in patients with these conditions. 

WARNINGS: Caution: Use carefully. May cause serious burns. Do not use over sensitive skin areas or in the presence of poor circulation. The unattended use of the device by children or incapacitated persons may be dangerous.

ADVERSE EFFECTS: Potential adverse effects that may occur as a result of the procedure include, but are not limited to, the onset or increase in: 

  • Eyelid/eye pain requiring discontinuation of the treatment procedure;
  • Eyelid irritation or inflammation;
  • Ocular surface irritation or inflammation; and
  • Ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light).
  • Physical pressure-induced injury to the eyelid; and
  • Ocular surface (corneal) infection.

ATTENTION
Reference the TearScience® LipiFlow® Thermal Pulsation System Instructions for Use for a complete listing of indications, warnings, and precautions.

1*vs. Acrysof IQ PanOptix®, TECNIS Symfony™, TECNIS® Multifocal. Based on comparison of DFU defocus curves and a head-to-head clinical study vs. PanOptix®
**Continuous 20/32 or better
*** Based on 15 patient study across 2 sites in US at 3-months post-operative follow-up
DOF2020CT4014 - Forte 1: A Comparative Clinical Evaluation of a New TECNIS® Presbyopia Correcting Intraocular Lens Against a PanOptix® Intraocular Lens- DEFOCUS CURVES AND VISUAL ACUITY RESULTS
2 TECNIS Eyhance® with TECNIS SimplicityTM Delivery System, Model DIB00 US DFU. Z311524E Rev. A, Jan. 2021. REF2021CT4019.
3 Data on File, Johnson & Johnson Surgical Vision, Inc. Jan. 2021. DOF2021CT4006.
4 2019 AllAboutVision.com. Contrast sensitivity testing by Gary Heiting, OD. (v0.1) - contrast sensitivity is a very important measure of visual function (p.1)
5 Zhao H, Mainster MA. Br J Ophthalmol. 2007; 91:1225–1229.
6 Zhao H, Mainster MA. Br J Ophthalmol. 2007; 91:1225–1229.
7 Krader CG.EUROTIMES 2011/2012;16/17: 18.
8 Data on File, DOF2018CT4007, Johnson & Johnson Surgical Vision, Inc. 2018
9 Piers P, Manzanera S, Prieto P, Gorceix N, Artal P. Use of adaptive optics to determine the optimal ocular spherical aberration. J Cataract Refract Surg. 2007 Oct;33(10):1721-62.
10 DOF2018OTH 4004 Johnson & Johnson Surgical Vision, Inc. 2018. (Modular transfer function (MTF) is a measure of the amount of contrast transferred by the optics in a visual system. The higher the MTF value, the more contrast transferred to the image, resulting in higher image contrast.)
11 Nagata M, Matsushima H, Mukai K, Terauchi W, Senoo T, Wada H, Yoshida S. Clinical evaluation of the transparency of hydrophobic acrylic intraocular lens optics. J Cataract Refract Surg. 2010 Dec;36(12):2056-60.
12 22 Van der Mooren M, Franssen L, Piers P. Effects of glistenings in intraocular lenses. Biomed Opt Express.
13 Auffarth GU, et al. Analysis of optical purity and optical quality of a new extended range of vision IOL. Poster presented at: The 20th ESCRS Winter Meeting; February2016, Athens, Greece.
14 Freeman W. Market Scope - 2017 IOL report: a global market analysis for 2016 to 2022. P. 79, 137, 174. REF2018MLT4002
*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
**Johnson & Johnson MedTech comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
*** Johnson & Johnson Vision supports investigators through independent research grants or direct funding.  
****Rajesh Rajpal is an employee of Johnson & Johnson Vision, Inc., serving as Chief Medical Officer and Global Head of Clinical and Medical Affairs.
‡Competitor platforms included are Hoya, Alcon & B&L Acrylic
‡‡Against IOLs that use Hoya, Alcon Acrylic, and B&L Silicone
‡‡‡Against Acrysof® IOL & Clareon IOL
‡‡‡‡Against Acrysof® IOL

© Johnson & Johnson Surgical Vision, 2022. All rights reserved.

PP2022OTH4749